CPI-0209 for Cancer and Lymphoma

This trial tests a new treatment called Tulmimetostat (also known as CPI-0209) for individuals with advanced solid tumors and lymphomas. The goal is to assess the safety and effectiveness of this medication when used alone or with other drugs across various cancer types. It suits those whose cancer has returned or hasn't responded to standard treatments, such as prostate cancer unresponsive to hormone therapy or specific genetic mutations. Participants will take Tulmimetostat daily, and some groups will also take another drug, enzalutamide. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the chance to be among the first to receive this new treatment.

The trial requires a washout period (time without taking certain medications) for prior systemic anticancer treatments, which must be stopped at least 4 weeks before the first dose of the study drug. Additionally, you must avoid medications or foods that are strong CYP3A inducers or inhibitors within 7 days prior to starting the study drug. Please consult with the trial team for specific guidance on your current medications.

Research has shown that Tulmimetostat, also known as CPI-0209, is generally safe. Studies found that doses of 200 mg and 300 mg are usually well-tolerated by patients with ovarian clear cell carcinoma and endometrial carcinoma, while a higher dose of 350 mg caused more side effects.

Tulmimetostat's safety profile is similar to other treatments targeting the EZH2 protein, which aids cell growth, meaning its side effects resemble those of other drugs in the same group.

Researchers are excited about Tulmimetostat because it targets the Enhancer of Zeste Homolog 2 (EZH2) enzyme, which plays a crucial role in regulating gene expression in cancer cells. Unlike traditional chemotherapy, which broadly attacks rapidly dividing cells, Tulmimetostat specifically inhibits EZH2, potentially leading to fewer side effects and more precise targeting of cancerous cells. Its oral administration makes it more convenient compared to many standard treatments that require intravenous delivery. This targeted approach, combined with ease of use, offers a promising new avenue for treating various cancers, including lymphoma and advanced solid tumors.

Research has shown that Tulmimetostat, also known as CPI-0209, holds promise in treating various types of cancer. In this trial, participants will receive Tulmimetostat in different cohorts, each targeting specific cancer types. Earlier studies found that patients with a type of prostate cancer unresponsive to hormone therapy experienced stable disease, meaning their cancer did not worsen. Additionally, patients with endometrial cancer and certain genetic changes showed positive responses. This drug blocks proteins called EZH2/EZH1, which can promote cancer growth. Early results suggest that targeting these proteins might slow or stop tumor growth in certain cancers. Although more research is needed, these findings are encouraging.¹³⁴⁶⁷